As a reminder, qualified EmblemHealth practitioners are eligible to obtain a waiver to offer buprenorphine, a medication approved by the Food and Drug Administration (FDA) for the treatment of opioid use disorders (OUD). Qualified practitioners include physicians, nurse practitioners (NPs), physician assistants (PAs), clinical nurse specialists (CNSs), certified registered nurse anesthetists (CRNAs), and certified nurse-midwifes (CNMs).
The DATA 20001 and SUPPORT Act2 expanded the use of medication-assisted treatment (MAT), and allow additional practitioners to obtain a waiver to treat opioid dependency with FDA-approved narcotic medications—including buprenorphine—in various settings.
To learn how to become a buprenorphine-waivered practitioner to treat opioid use disorder, visit the Substance Abuse and Mental Health Services Administration (SAMHSA) website .
1 Drug Addiction Treatment Act of 2000.
2 SUPPORT (Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment) for Patients and Communities Act of 2018.
JP# 56547 07/2022
